Literature DB >> 8939725

Regulation of differentiation by TGF-beta.

H L Moses1, R Serra.   

Abstract

Recent experiments in neural, skeletal, endothelial, and hematopoietic tissues have provided new insights into the way members of the transforming growth factor-beta (TGF-beta) superfamily regulate cellular differentiation. TGF-betas regulate the fate of multipotential stem cells instructively (in the neural crest) by regulating the expression or function of tissue-specific transcription factors, as well as selectively (in the mesenchyme) by regulating the expression of required growth factors and their receptors. During skeletal development, TGF-betas have unique functions and act sequentially to modulate chondrocyte and osteoblast differentiation. Responsiveness to TGF-betas changes as cells differentiate and evidence now suggests that changes in TGF-beta receptor profile may account for some of these differences. Drosophila and transgenic mouse models are now providing useful insights into mechanisms of TGF-beta action in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8939725     DOI: 10.1016/s0959-437x(96)80087-6

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  47 in total

1.  Mechanisms of transforming growth factor-beta receptor endocytosis and intracellular sorting differ between fibroblasts and epithelial cells.

Authors:  J J Doré; D Yao; M Edens; N Garamszegi; E L Sholl; E B Leof
Journal:  Mol Biol Cell       Date:  2001-03       Impact factor: 4.138

2.  TGF-beta mediated Msx2 expression controls occipital somites-derived caudal region of skull development.

Authors:  Ryoichi Hosokawa; Mark Urata; Jun Han; Armen Zehnaly; Pablo Bringas; Kazuaki Nonaka; Yang Chai
Journal:  Dev Biol       Date:  2007-08-06       Impact factor: 3.582

3.  Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.

Authors:  Reema Wahdan-Alaswad; J Chuck Harrell; Zeying Fan; Susan M Edgerton; Bolin Liu; Ann D Thor
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

4.  Tgfbr2 is required in osterix expressing cells for postnatal skeletal development.

Authors:  Sarah B Peters; Ying Wang; Rosa Serra
Journal:  Bone       Date:  2016-12-30       Impact factor: 4.398

5.  Assembly of the prothrombinase complex on the surface of human foreskin fibroblasts: Implications for connective tissue growth factor.

Authors:  Mario C Rico; James J Rough; Joanne M Manns; Fabiola Del Carpio-Cano; Fayez F Safadi; Satya P Kunapuli; Raul A DeLa Cadena
Journal:  Thromb Res       Date:  2011-09-01       Impact factor: 3.944

Review 6.  TGF-β Family Signaling in Connective Tissue and Skeletal Diseases.

Authors:  Elena Gallo MacFarlane; Julia Haupt; Harry C Dietz; Eileen M Shore
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

7.  HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis.

Authors:  Tetsu Hayashida; Fumiyuki Takahashi; Naokazu Chiba; Elena Brachtel; Motomi Takahashi; Nadia Godin-Heymann; Kenneth W Gross; Maria d M Vivanco; Vasuki Wijendran; Toshihiro Shioda; Dennis Sgroi; Patricia K Donahoe; Shyamala Maheswaran
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

Review 8.  Hand in glove: brain and skull in development and dysmorphogenesis.

Authors:  Joan T Richtsmeier; Kevin Flaherty
Journal:  Acta Neuropathol       Date:  2013-03-23       Impact factor: 17.088

9.  Molecular profiling of the developing mouse axial skeleton: a role for Tgfbr2 in the development of the intervertebral disc.

Authors:  Philip Sohn; Megan Cox; Dongquan Chen; Rosa Serra
Journal:  BMC Dev Biol       Date:  2010-03-09       Impact factor: 1.978

10.  Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.

Authors:  Anita L Bane; Dushanthi Pinnaduwage; Sarah Colby; Michael Reedijk; Sean E Egan; Shelley B Bull; Frances P O'Malley; Irene L Andrulis
Journal:  Breast Cancer Res Treat       Date:  2008-06-18       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.